Cell therapy biotech developing a novel off-the-shelf approach with proprietary and first-in-class engineered CIR™NK cells that target HLA-G, expressed in over 50% of hematologic and solid tumors.

Our unique technology enhances NK cell potency and functional persistence to safely increase depth and duration of response, while improving patient access, scalability, speed and profitability.